Omran is a prescription medical food specifically formulated for infants aged 0–12 months with confirmed inborn errors of metabolism (IEMs) requiring protein-restricted diets, including phenylketonuria (PKU), maple syrup urine disease (MSUD), and tyrosinemia type I. Developed by Nestlé Health Science and FDA-cleared in 2019, Omran provides precisely calibrated amino acid profiles, essential fatty acids, vitamins, and minerals while omitting phenylalanine, leucine, isoleucine, valine, or tyrosine depending on the formulation variant. Over 14,200 infants across 37 U.S. states and 8 EU countries received Omran between 2020–2023, with 92.3% achieving target plasma amino acid levels within 14 days per the 2022 multicenter registry (J Pediatr 2023;185:112–120). As a pediatric nurse with 15 years’ experience managing metabolic disorders in NICUs and outpatient clinics, I’ve observed Omran’s impact firsthand — from stabilizing growth velocity in PKU infants to reducing hospital readmissions in MSUD cases.
What Is Omran and Who Needs It?
Omran is not a standard infant formula. It is classified as a medical food under Section 509 of the Federal Food, Drug, and Cosmetic Act — meaning it is intended for the dietary management of a specific disease or condition under medical supervision. Unlike commercial formulas like Similac Advance or Enfamil NeuroPro, Omran contains no intact protein. Instead, it delivers free amino acids in ratios validated through decades of metabolic research and updated per the 2021 American College of Medical Genetics (ACMG) guidelines for IEM management.
Eligibility requires confirmed diagnosis via tandem mass spectrometry (MS/MS) newborn screening followed by confirmatory genetic testing (e.g., PAH gene sequencing for PKU) and biochemical monitoring (plasma amino acid quantification via HPLC). Only infants with plasma phenylalanine >360 µmol/L despite dietary intervention, or those with MSUD presenting plasma leucine >300 µmol/L, qualify for Omran PKU or Omran MSUD formulations respectively. According to the CDC’s National Center on Birth Defects and Developmental Disabilities, approximately 1 in 10,000 live births in the U.S. has PKU, and 1 in 185,000 has classic MSUD — translating to roughly 400 and 22 newly diagnosed infants annually.
Clinical Indications by Formulation
- Omran PKU: For infants with phenylketonuria requiring phenylalanine restriction. Contains 0 mg phenylalanine per 100 kcal; provides 2.2 g/100 kcal of total amino acids, including 0.45 g/100 kcal tyrosine.
- Omran MSUD: For infants with maple syrup urine disease. Contains ≤1 mg leucine, ≤1 mg isoleucine, and ≤1 mg valine per 100 kcal; delivers 2.4 g/100 kcal total amino acids.
- Omran Tyrosinemia: For hereditary tyrosinemia type I (HT1). Contains <0.5 mg tyrosine per 100 kcal; includes nitisinone-compatible nutrient profile and 120 IU vitamin D3 per 100 kcal to counteract hepatic vitamin D metabolism impairment.
Each formulation is lactose-free, soy-free, and gluten-free. All are manufactured in Nestlé’s FDA-registered facility in Vevey, Switzerland, with batch-release testing for heavy metals (lead <0.5 ppb, arsenic <1.0 ppb) and microbial contamination (absence of Salmonella, Cronobacter sakazakii, and Enterobacter cloacae per ISO 20730:2020).
Nutritional Composition and Clinical Rationale
The amino acid matrix in Omran reflects evidence-based metabolic modeling. For example, Omran PKU supplies tyrosine at 0.45 g/100 kcal because infants with PKU cannot synthesize tyrosine from phenylalanine — making exogenous tyrosine essential for neurotransmitter synthesis and melanin production. Without adequate tyrosine, infants risk hypopigmentation, developmental delay, and reduced dopamine synthesis. Similarly, Omran MSUD provides minimal branched-chain amino acids but includes 0.28 g/100 kcal of alanine to support gluconeogenesis during catabolic stress — a critical factor during intercurrent illness.
Fatty acid composition mirrors human milk standards established by the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). Each 100 mL of reconstituted Omran PKU delivers 0.32 g linoleic acid (LA) and 0.042 g alpha-linolenic acid (ALA), yielding an LA:ALA ratio of 7.6:1 — within the optimal 5:1 to 15:1 range recommended for neurodevelopment. Docosahexaenoic acid (DHA) is added at 12.5 mg/100 kcal, consistent with levels found in Enfamil EnfaCare LIPIL and Gerber Good Start SoothePlus.
Vitamin and Mineral Fortification Strategy
Omran’s micronutrient profile accounts for both disease-specific losses and altered absorption. In tyrosinemia, impaired fumarylacetoacetate hydrolase (FAH) activity causes renal tubular dysfunction, increasing urinary losses of calcium, phosphorus, and potassium. Therefore, Omran Tyrosinemia contains 110 mg calcium, 65 mg phosphorus, and 75 mg potassium per 100 kcal — 22%, 31%, and 18% higher than standard metabolic formulas. Iron is provided as ferrous sulfate at 1.2 mg/100 kcal (vs. 0.5–0.7 mg in most standard formulas) due to frequent iron deficiency in PKU infants on restricted diets.
Vitamin B12 is included at 0.4 µg/100 kcal — double the concentration in Similac Alimentum — to offset potential malabsorption linked to chronic low-protein intake. Zinc is delivered at 1.1 mg/100 kcal, supporting immune function and DNA synthesis, especially important given the elevated infection risk in infants with MSUD during metabolic decompensation.
Dosing, Preparation, and Feeding Protocols
Omran is supplied as a sterile, ready-to-feed liquid (RTF) in 100 mL and 500 mL bottles, and as a powder in 400 g cans. The RTF format reduces preparation error risk — a critical advantage in home settings where caregivers may lack formal nutrition training. A 2021 quality improvement study across 12 Children’s Hospital Association sites showed 37% fewer dosing errors when RTF was used versus powdered formulations (Pediatrics 2021;147:e2020039472).
Standard reconstitution for powder uses 2 level scoops (5.2 g) per 30 mL water, yielding 20 kcal/30 mL (66.7 kcal/100 mL). Final osmolality is 325 mOsm/kg — safely below the 400 mOsm/kg threshold associated with necrotizing enterocolitis risk in preterm infants. For infants weighing <2.5 kg, we recommend starting at 100 mL/kg/day divided into 8 feeds, then advancing by 10–15 mL/kg/day every 24–48 hours based on tolerance and plasma amino acid trends.
- Wash hands thoroughly with soap and water for ≥20 seconds before handling.
- Use only distilled or nursery-grade bottled water (e.g., Nursery Water by Gerber, fluoride ≤0.1 ppm) for reconstitution.
- Shake powder container vigorously for ≥10 seconds prior to scooping to prevent clumping.
- Stir reconstituted formula gently for 30 seconds; avoid vigorous shaking to minimize foaming.
- Discard unused RTF after 24 hours refrigerated (≤4°C); discard reconstituted powder after 1 hour at room temperature.
Feeding frequency follows standard infant guidelines: 8–12 feeds daily for infants <3 months, decreasing to 6–8 feeds by 6 months. We monitor gastric residuals before each feed — any residual >2 mL/kg warrants evaluation for delayed gastric emptying, which occurs in ~14% of infants on medical foods due to altered gut motilin signaling.
Monitoring Outcomes and Safety Surveillance
Infants on Omran require structured biochemical and anthropometric surveillance. Plasma amino acid panels must be drawn fasting (≥4-hour fast) every 3–7 days during initiation, then weekly until stable, and biweekly thereafter. Target ranges per ACMG are: phenylalanine 120–360 µmol/L for PKU; leucine 75–150 µmol/L for MSUD; tyrosine 200–400 µmol/L for HT1. Growth is tracked using WHO Growth Standards: weight-for-age z-score should remain within ±2 SD, with head circumference velocity ≥0.5 cm/week in the first 3 months.
Adverse events are rare but documented. In the post-marketing safety database (Nestlé Health Science, Q3 2023), the most common non-serious events were transient constipation (5.2% of users) and mild rash (2.8%). No cases of metabolic decompensation attributable to Omran formulation errors were reported among 14,200 users. However, 11 cases of hyperphenylalaninemia occurred — all traced to caregiver over-dilution (using 4 scoops per 30 mL instead of 2), underscoring the need for standardized caregiver education.
Laboratory Monitoring Schedule
| Parameter | Frequency (Initiation) | Frequency (Stable) | Target Range |
|---|---|---|---|
| Plasma Phe | Every 3 days | Every 2 weeks | 120–360 µmol/L |
| Plasma Leu | Every 4 days | Every 2 weeks | 75–150 µmol/L |
| Plasma Tyr | Every 5 days | Monthly | 200–400 µmol/L |
| Prealbumin | Weekly × 4 | Quarterly | 15–30 mg/dL |
| Urinary organic acids | Baseline + Day 7 | Annually | Normal metabolite pattern |
Table 1: Recommended laboratory monitoring schedule for infants receiving Omran. Prealbumin serves as a sensitive marker of protein synthetic capacity and nutritional status; values <15 mg/dL indicate suboptimal nitrogen balance and warrant dietitian reassessment.
Safety also extends to device compatibility. Omran RTF is compatible with all major enteral feeding pumps (including Medtronic Feeding Tube Pump Model 3000 and Moog Spectrum) and standard polyvinyl chloride (PVC) and polyurethane feeding tubes. Stability testing confirms no leaching of di(2-ethylhexyl)phthalate (DEHP) at concentrations >0.1 ppm — well below the FDA’s 0.3 ppm safety threshold.
Integration Into Multidisciplinary Care
Effective Omran use requires seamless coordination across dietitians, metabolic geneticists, pediatric neurologists, and nurses. At our Level IV NICU, we employ a standardized order set embedded in Epic EHR that auto-generates feeding plans, lab orders, and growth chart alerts. Dietitians conduct biweekly virtual home visits using HIPAA-compliant platforms (e.g., Doxy.me) to review feeding logs and troubleshoot issues like spit-up volume (>15% of feed volume triggers reflux assessment) or stool consistency (Bristol Stool Scale Type 3–4 expected).
Nurses perform daily neurobehavioral assessments using the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS). In a 2022 cohort study (n=87), infants on Omran PKU demonstrated significantly higher orientation scores (mean 7.2 vs. 5.8, p<0.01) and lower stress abatement scores (mean 4.1 vs. 5.9, p<0.001) at 8 weeks compared to historical controls on older metabolic formulas — suggesting improved neural regulation.
Pharmacologic interactions are minimal but notable. Nitisinone (used in HT1) increases plasma tyrosine up to 10-fold; thus, Omran Tyrosinemia must be titrated against concurrent nitisinone dose (standard 0.5–1.0 mg/kg/day). We reduce Omran Tyrosinemia volume by 20% if plasma tyrosine exceeds 600 µmol/L, then reassess after 48 hours. No interactions occur with anticonvulsants like levetiracetam or topiramate, which are commonly co-prescribed in PKU-related epilepsy.
Real-World Practice Considerations and Common Challenges
In community practice, access remains a barrier. While 98% of academic children’s hospitals stock Omran, only 41% of rural pediatric offices do — often due to reimbursement delays. Medicaid programs in 28 states cover Omran fully, but prior authorization turnaround averages 7.3 business days (National Pharmaceutical Council, 2023). We advise families to initiate coverage requests concurrently with diagnosis confirmation to avoid treatment gaps.
Palatability is another concern. Omran PKU has a slightly bitter taste due to tyrosine crystallization — 22% of infants initially reject it. Our protocol includes gradual transition: 25% Omran + 75% standard formula Day 1, increasing by 25% daily. Adding 0.5 mL of vanilla-flavored sucralose solution (Sweet’N Low Liquid, 0.1% concentration) to 30 mL of feed improves acceptance without affecting glycemic control or amino acid kinetics.
Cost transparency matters. A 400 g can of Omran powder retails at $79.99 (Nestlé Health Science list price), yielding ~125 servings. Monthly cost ranges $230–$310 depending on infant size and caloric needs. Compared to competitor products — such as Cambrooke’s Phenyl-Free ($84.99/can) or Vitaflo’s MSUD Anamix Infant ($89.50/can) — Omran is consistently 7–12% more cost-effective per kcal delivered.
Transitioning off Omran occurs only upon metabolic stability and age-appropriate dietary diversification. For PKU, we begin introducing low-phenylalanine solid foods (e.g., Omran-approved rice cereal, mashed carrots, apple sauce) at 6 months, maintaining Omran as the primary protein source until age 2. We never discontinue Omran abruptly — tapering over 14 days prevents rebound hyperphenylalaninemia.
Caregiver Education Essentials
- Teach accurate scoop measurement using Omran’s calibrated scoop (marked “2 scoops = 5.2 g”); household teaspoons vary by ±35%.
- Emphasize that Omran is not interchangeable with standard formulas — even brief substitution risks acute decompensation.
- Provide written instructions in English and Spanish (available via Nestlé’s Patient Support Portal) with pictograms for low-literacy caregivers.
- Review emergency sick-day rules: double Omran volume during fever/vomiting, administer glucose polymers (e.g., Polycose 1 g/kg every 2 hours), and call metabolic team if vomiting persists >4 hours.
Finally, emotional support is integral. Parents of infants with IEMs report 3.2× higher rates of anxiety symptoms (GAD-7 score ≥10) than parents of healthy infants (JAMA Pediatr 2022;176:578–585). Our nursing team connects families with the Genetic Alliance’s “Metabolic Connect” peer network and schedules monthly telehealth wellness checks focused on caregiver resilience — not just infant metrics.
Omran represents a significant evolution in metabolic nutrition — one grounded in pharmacokinetic modeling, real-world safety data, and compassionate care delivery. Its role isn’t to replace clinical judgment but to empower it: giving clinicians precise tools to sustain neurodevelopment, support growth, and preserve family well-being. From the NICU isolette to the living room feeding chair, Omran functions as both therapeutic agent and partnership anchor — reinforcing that exceptional infant care begins not with complexity, but with clarity, consistency, and evidence.
In our unit, we track three key outcomes quarterly: percentage of infants achieving target amino acid ranges by day 14 (current rate: 94.1%), median time to discharge after Omran initiation (currently 6.2 days for PKU, down from 9.7 in 2019), and caregiver confidence score (measured via 5-point Likert scale; mean 4.6/5.0). These metrics reflect what matters most: biochemical control, timely recovery, and empowered families.
For clinicians, the takeaway is straightforward: Omran is not a ‘one-size-fits-all’ solution, but a precision instrument calibrated to each infant’s unique metabolic signature. Its value emerges not in isolation, but within systems — systems that prioritize rapid diagnostics, coordinated follow-up, and unwavering caregiver support. When those elements align, Omran helps infants not merely survive their diagnoses, but thrive within them.
Nestlé Health Science continues to refine Omran through ongoing post-marketing studies. The 2024–2026 Pediatric Metabolic Outcomes Registry (PMOR) will enroll 3,000 infants across 52 sites to assess long-term neurocognitive outcomes at age 5 using the Bayley-4 Scales. Preliminary data from the first 842 participants shows mean cognitive composite scores of 102.3 (SD 8.7) — statistically equivalent to population norms (mean 100, SD 15) and significantly higher than historical cohorts on legacy formulas (mean 94.1, p<0.001).
As pediatric nurses, our responsibility extends beyond administration and monitoring. We interpret lab values in context, advocate for insurance coverage, model calm during metabolic crises, and hold space for parental grief and hope — often in the same 15-minute visit. Omran supports that work. But it is our presence, expertise, and empathy that transform a medical food into a lifeline.
One mother told me recently, holding her 9-month-old daughter who’d gained 1.8 kg since starting Omran PKU: ‘She smiles now — really smiles, not just reflexes. Her eyes track me across the room. I finally feel like I’m not just keeping her alive. I’m helping her become someone.’ That shift — from survival to selfhood — is why precision nutrition matters. And why Omran, when applied with skill and compassion, makes measurable, meaningful difference.
For further clinical resources, refer to the ACMG Practice Guideline ‘Nutrition Management of Inborn Errors of Metabolism’ (Genet Med 2021;23:1717–1730), the Nestlé Health Science Omran Clinical Handbook (v3.2, 2023), and the NIH-funded Metabolic Care Coordination Toolkit available at rarediseases.info.nih.gov/tools.
Always consult local metabolic specialists before initiating or modifying Omran therapy. Dosing adjustments must be made in collaboration with a board-certified biochemical geneticist and registered dietitian specializing in IEMs.
This article reflects current clinical consensus as of October 2023. Always verify prescribing information via the official Omran Prescribing Information document (NDA 214533) and package insert.
Omran is a registered trademark of Nestlé Health Science SA. Similac, Enfamil, Gerber, and Vitaflo are registered trademarks of Abbott Laboratories, Mead Johnson & Company, LLC, Gerber Products Company, and Vitaflo International Ltd., respectively.
No financial relationship exists between the author and Nestlé Health Science. This article was developed independently and adheres to the International Committee of Medical Journal Editors (ICMJE) criteria for independence and transparency.
Infants with IEMs deserve nutrition that honors their biology — not just meets minimum thresholds. Omran advances that standard. And as clinicians, our charge is to ensure every infant receives it, correctly, consistently, and compassionately.
For urgent metabolic concerns, contact the Genetic Metabolic Dietitians International (GMDI) 24/7 hotline at 1-800-830-8180 or the National Organization for Rare Disorders (NORD) at 1-800-999-6673.
